Having trouble accessing articles? Reset your cache.

Innodia: Surrounding diabetes

In a slight twist on the typical NRDO business model, Innodia Inc. has no internal research capabilities of its own, relying on a network of academic and corporate partnerships to in-license Type II diabetes candidates that are within 18 months of an IND. Its strategy is to develop an array of oral small

Read the full 533 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers